Triple Therapy in T1DM

NCT03899402 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether adding dapagliflozin to standard treatment helps lower HbA1c levels in people with type 1 diabetes.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 78 people

Who can join Ages 18–75 · all sexes

Timeline Started 2019-05 · est. completion 2026-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03899402 ↗

Description as written by the study sponsor.

To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.

Treatments tested

Insulin Drug

Standard of care insulin for pump or injection and serves as a control
Semaglutide also known as Ozempic Drug

Injectable weekly GLP-1RA given as open label experimental drug
Dapagliflozin also known as Farxigo Drug

Oral daily SGLT2 Inhibitor given as experimental drug
Placebo to Dapagliflozin Drug

Placebo to Dapagliflozin given as a control to the experimental drug

Main thing measured	Change in HbA1c following dapagliflozin
Sponsor	State University of New York at Buffalo
Conditions studied	Type 1 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03899402 ↗